Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study.
Steinhubl
S R
SR
Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, Lackland, TX, USA. steven.steinhubl@59MDW.WHMC.AF.MIL.
D000818:Animals; D003327:Coronary Disease / Q000150:complications / Q000628:therapy*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects*; D010979:Platelet Function Tests / Q000295:instrumentation / Q000379:methods; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D019095:Point-of-Care Systems
D019039:Platelet Glycoprotein GPIIb-IIIa Complex